Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Gynae-Oncology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
R4018-ONC-1721A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer | |
|---|---|
| Local Project Reference: | 110877 |
| Principal Investigator: | Dr Rowan Miller |
| Drug Class/Treatment: | REGN4018 (MUC16xCD3 Bispecific Antibody) Monotherpay or Combination with Cemiplimab |
| Patient Population: | Recurrent Ovarian Cancer (advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer) |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
CRAINA phase 1b TiTE-CRM dose escalation clinical trial of tolinapant in combination with standard radical chemoradiotherapy in cervical cancer | |
|---|---|
| Local Project Reference: | 51584 |
| Principal Investigator: | Dr Asma Sarwar |
| Drug Class/Treatment: | Tolinapant (ASTX660) - non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Combination with standard radical chemoradiotherapy |
| Patient Population: | Cervical Cancer
|
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
